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Colorectal cancer is a common disease with high mortality.
Suitable biomarkers for detection of tumors at an early
curable stage would signiﬁcantly improve patient survival.
Here, we show that the SPG20 (spastic paraplegia-20)
promoter, encoding the multifunctional Spartin protein,
is hypermethylated in 89% of colorectal carcinomas,
78% of adenomas and only 1% of normal mucosa samples.
SPG20 methylation was also present in a pilot series of stool
samples and corresponding tumors from colorectal cancer
patients. SPG20 promoter hypermethylation resulted in loss
of mRNA expression in various cancer types and subsequent
depletion of Spartin. We further showed that Spartin down-
regulation in cancer cells resulted in cytokinesis arrest,
which was reversed when SPG20 methylation was inhibited.
The present study identiﬁes SPG20 promoter hypermethy-
lation as a biomarker suitable for non-invasive detection
of colorectal cancer, and a possible mechanism for cyto-
kinesis arrest in colorectal tumorigenesis.
Oncogene (2011) 30, 3967–3978; doi:10.1038/onc.2011.109;
published online 18 April 2011
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Introduction
Colorectal cancer is the second and third most common
cause of cancer deaths among men and women in
Europe and the United States, respectively (Ferlay et al.,
2007; Jemal et al., 2009). The survival of colorectal
cancer patients is strongly associated with the tumor
stage at the time of diagnosis. Patients with metastasis to
distant organs have a poor 5-year survival (11%),
whereas most patients with a localized disease have
good prognosis (90%) (Jemal et al., 2009). As develop-
ment of a colorectal carcinoma from an adenoma may
take several years, there is a large window of opportu-
nity to detect tumors at a curable stage. Early detection
of cancer and of precursor lesions followed by surgical
removal would signiﬁcantly reduce the number of cancer
deaths. Although the quality of existing diagnostics and
screening programs for colorectal cancer continues to
improve, the sensitivity and speciﬁcity of non-invasive
tests are still suboptimal.
Epigenetic alterations are deﬁned as non-sequence-
based modiﬁcations that are inherited through cell
division (Feinberg et al., 2006). In the last decade such
changes have been recognized to be at least as common
as genetic changes in human cancer (Jones and Baylin,
2002). DNA methylation is the best studied epigenetic
mechanism, and the presence of too much methylation
(hypermethylation) in gene promoters may disrupt
function by reducing or silencing gene expression. In
colorectal cancer, several hypermethylated target genes
have been identiﬁed in malignant tumors as well as
in early benign precursor lesions (Lind et al., 2007;
reviewed by Zitt et al. (2007) and Kim et al. (2010)). If
such targets additionally showed high sensitivity and
speciﬁcity for colorectal tumors, they would be suitable
for early detection of colorectal cancer.
In a previous epigenome study, we identiﬁed a list of
genes that potentially could be inactivated owing to
promoter hypermethylation in colorectal cancer (Lind
et al., 2006). One of these candidates, SPG20 (spastic
paraplegia-20), has been analyzed in the present study
for its suitability as a biomarker in colorectal cancer and
for its functional mechanism.
The SPG20 gene is located in chromosome band
13q13.3 and a one base deletion in exon-4 (1110delA)
resulting in loss of expression of the mutated protein has
been shown to cause the autosomal recessive spastic
paraplegia-20 (Troyer syndrome) (Patel et al., 2002;
Bakowska et al., 2008). The hereditary spastic para-
plegias describe a group of inherited neurological dis-
orders characterized by progressive muscle stiffness
(spasticity) and development of paralysis (paraplegia)
of the lower limbs (Proukakis et al., 2004).
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www.nature.com/oncSPG20 encodes Spartin, which contains a Micro-
tubule-Interacting and Trafﬁcking molecule (MIT)
domain in the N-terminus and sequence similarities
with a number of uncharacterized plant proteins in the
C-terminus (Ciccarelli et al., 2003). Spartin is a multi-
functional protein and has previously been found to
be involved in intracellular epidermal growth factor
receptor trafﬁcking (Bakowska et al., 2007) and in lipid
droplet turnover (Eastman et al., 2009; Hooper et al.,
2010). It has also been reported to be an adaptor for the
homologous to the E6-AP carboxyl terminus (HECT)
domain-containing E3 ubiquitin ligases (Edwards et al.,
2009; Milewska et al., 2009; Hooper et al., 2010) and an
inhibitor of bone morphogenic protein (BMP) signaling
(Tsang et al., 2009).
In the present study, the promoter methylation status
of the SPG20 gene was determined in test and validation
series of colorectal carcinomas, adenomas and normal
mucosa. The methylation status was compared with
mRNA expression levels in several cancer cell lines of
various types. We show that the SPG20 promoter is
hypermethylated in almost all colorectal carcinomas and
adenomas, causing the expression of Spartin to be
undetectable, whereas there is no hypermethylation of
SPG20 in normal mucosa. Interestingly, we identify
cytokinesis arrest as a functional consequence of Spartin
downregulation, a condition thought to be associated
with carcinogenesis. We therefore propose that SPG20
hypermethylation could represent both a mechanism
and a biomarker in colorectal carcinogenesis.
Results
Identiﬁcation of SPG20 as a biomarker for colorectal
cancer
By using microarray gene expression proﬁling in
combination with epigenetic drug treatment (5-aza-
20deoxycytidine (AZA)) of colon cancer cell lines we
have previously identiﬁed SPG20 as a DNA methylation
candidate in colorectal cancer (Lind et al., 2006). In the
present study, we found that the promoter of the SPG20
gene was hypermethylated in 20/20 colon cancer cell
lines. A test set comprising 74 colorectal carcinomas, 60
adenomas and 51 normal mucosa samples was analyzed
by quantitative methylation-speciﬁc PCR (qMSP).
SPG20 was found to be methylated in 91%, 75% and
2% of the samples, respectively. Likewise, in a clinically
independent validation set consisting of 105 colorectal
carcinomas, 51 adenomas and 59 normal mucosa
samples, SPG20 was methylated in 88%, 82% and 0%
of the samples, respectively (Table 1). The methylation
status of the SPG20 promoter showed no association
with the MSI status of the analyzed carcinomas. None
(0%) of the normal mucosa samples taken in distance
from the carcinomas (n¼105) was methylated. For the
combined test and validation series, Receiver Operating
Characteristics (ROC) curves showed an area under
the curve (AUC) of 0.947 (P¼2.87E-37; asymptotic
95% conﬁdence interval: 0.919–0.975) for carcinomas
versus normal mucosa and 0.913 (P¼2.66E-26; asymp-
totic 95% conﬁdence interval: 0.872–0.954) for adeno-
mas versus normal mucosa (Figure 1). SPG20
methylation was also detected in 6/9 (67%) stool
samples from patients with methylated carcinomas.
From one patient two stool samples were taken,
collected proximally and distally to the carcinoma
during open surgery. Both the carcinoma and the distal
stool sample were methylation-positive, whereas the
proximal stool sample was unmethylated. Direct bisul-
ﬁte sequencing of the SPG20 promoter in colon cancer
cell lines conﬁrmed the DNA methylation status as
assessed by MSP (Supplementary Figure S1). These
results indicate that the SPG20 promoter is hypermethy-
lated in the majority of colorectal carcinomas and
adenomas, but very rarely in normal colonic epithelium,
and that SPG20 methylation is a suitable biomarker for
non-invasive analysis.
Real-time quantitative analysis shows that SPG20
promoter hypermethylation causes loss of gene expression
In order to examine the relationship of aberrant
promoter methylation with gene expression, cancer cell
lines, colorectal carcinomas and normal mucosa samples
were subjected to quantitative real-time PCR analysis.
The level of mRNA expression of SPG20 was strongly
associated with promoter methylation status in cancer
cell lines (P¼2.0E-6; Figure 2a) and tissue samples
(P¼4.0E-6, normals and carcinomas; P¼0.008, only
carcinomas). Measurements of mRNA levels in six
colon cancer cell lines treated with epigenetic drugs
(AZA and trichostatin-A (TSA)) also indicated an
association between SPG20 promoter hypermethylation
and gene expression. The mRNA levels of SPG20 were
Table 1 Frequency and distribution of promoter methylation levels (PMR values) in normal colorectal mucosas, adenomas and carcinomas as
measured by qMSP
SPG20 Normal mucosas Adenomas Carcinomas P-value
a
n (%) Median (IQR) n (%) Median (IQR) n (%) Median (IQR)
Test set 1/51 (2%) 0.49 (1.18) 45/60 (75%) 20.17 (33.13) 67/74 (91%) 44.77 (47.15) 5.32E-21
Validation set 0/59 (0%) 1.88 (2.13) 42/51 (82%) 29.25 (47.08) 92/105 (88%) 37.29 (35.41) 9.27E-24
Combined (test and validation) 1/110 (1%) 1.17 (2.36) 87/111 (78%) 23.97 (33.85) 159/179 (89%) 39.21 (39.84) 1.33E-42
Abbreviations: IQR, interquartile range (75th percentile–25th percentile); n, number of positive cases; PMR, percentage methylated reference;
qMSP, quantitative methylation-speciﬁc PCR; SPG20, spastic paraplegia-20.
aKruskal–Wallis test.
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Oncogeneupregulated in ﬁve of the six methylated cell lines after
drug treatment (Figure 2b). These analyses show that
the promoter hypermethylation found in colon cancer
reduces the cellular levels of SPG20 mRNA.
Hypermethylated colon cancer cell lines do not express
the SPG20 protein product Spartin
As the hypermethylated cell lines did not express SPG20
mRNA, we wanted to conﬁrm this transcription deﬁ-
ciency on the protein level. The SPG20 gene encodes the
666-amino-acid (80-kDa) protein, Spartin (Bakowska
et al., 2005; Robay et al., 2006). In addition to the
normal colon epithelial cell line CRL-1790, four colon
cancer lines with hypermethylated SPG20 promoter
were analyzed: two microsatellite unstable (MSI;
HCT116 and RKO) and two microsatellite stable
(MSS; SW480 and HT29) lines. As expected, they did
not express detectable amounts of Spartin by western
blotting or by immunoﬂuorescence confocal micro-
scopy, as opposed to the control line (Figure 3),
conﬁrming the results from the mRNA analysis.
Spartin localizes to the spindle poles and the cytokinesis
bridge of dividing daughter cells
Spartin is a multifunctional protein with a broad
subcellular localization pattern (Lu et al., 2006; Robay
et al., 2006; Bakowska et al., 2007; Eastman et al., 2009;
Edwards et al., 2009; Tsang et al., 2009; Renvoise et al.,
2010). In addition to diffuse cytosolic staining, we could
clearly see that Spartin localized to the cytokinesis
bridge of dividing daughter cells in CRL-1790 cells
(Figure 3c, arrow in panel b). As the CRL-1790 cells had
very few cytokinesis proﬁles, we continued our studies
on the localization of endogenous Spartin in HeLa and
hTERT RPE-1 cells. We could observe a very similar
localization pattern in these cells, with diffuse cyto-
solic staining colocalizing with a-tubulin in interphase
cells (Supplementary Figure S2) and localization to
the cytokinesis bridge of late cytokinesis proﬁles. In
prometaphase cells, Spartin showed very strong dis-
tribution at the spindle poles in HeLa, CRL-1790
(Figures 4g–k) and hTERT RPE-1 (Supplementary
Figure S3) cells but not in the four colon cancer cell
lines (Supplementary Figure S4).
Colon cancer cell lines contain several cytokinesis proﬁles
The immunoﬂuorescence confocal microscopy analyses
suggested that the various cell lines had different growth
rates (Figures 3b–g). We consequently analyzed the
relative proliferation rates and found that the colon
cancer cell lines proliferated four to 13 times faster than
the control line (Figure 5a).
The cells were simultaneously analyzed for the
numbers of cytokinesis proﬁles by using the cytokin-
esis markers Aurora-B and a-tubulin (Carmena and
Earnshaw, 2003; Steigemann and Gerlich, 2009). All
four cell lines had a signiﬁcantly higher number of cells
in cytokinesis than the control line (Figure 5b). Inter-
estingly, we could observe a correlation between
proliferation rate and the number of cytokinesis bridges.
The cell lines with the highest proliferation rate
(HCT116 and RKO) showed a moderate increase in
the number of cells in cytokinesis, whereas the slower
growing cell lines (HT29 and SW480) showed a high
number of cells interconnected by a cytokinesis bridge
(Figure 5). Taken together, these observations indicate a
delay in cytokinesis in HT29 and SW480.
Colon cancer cell lines have convoluted cytokinesis bridges
Many of the cytokinesis bridges in HT29 and SW480
were kinked, nicked or convoluted, indicating problems
with the ﬁnal abscission step (Figure 6). This was
particularly noticeable in SW480. Bridges that appeared
to be normal often turned out to be kinked when
watched in a side view in three-dimensional reconstruc-
tions from confocal z-stack images (Supplementary
Figure S5). In many of the cytokinesis proﬁles, the
localization of Aurora-B was dispersed along the length
of the bridge (Figures 6a, c and e, and Supplementary
Figure S5), indicating that these cells were in a very late
stage of cytokinesis, when Aurora-B is transported back
toward the cell body (Murata-Hori et al., 2002).
Occasionally we observed three cells linked together
through cytokinesis bridges, resembling pearls on a
string (Supplementary Figure S6). Interestingly, we also
observed examples of DNA-containing intercellular
bridges in these cells (Supplementary Figure S7). In
contrast to the slower growing HT29 and SW480, the
highly proliferative HCT116 and RKO cells and the
CRL-1790 control cells showed more normal-looking
cytokinesis bridges (Figures 5c and d, and Supplemen-
tary Figure S5). Taken together, these observations
indicate that SPG20-hypermethylated colon cancer cell
lines are hampered in their completion of cytokinesis.
Figure 1 ROC curves show that SPG20 is a biomarker for
colorectal carcinomas and adenomas. The area under the ROC
curve (AUC) signiﬁes the accuracy of the SPG20 biomarker for
distinguishing colorectal carcinomas (blue line) and adenomas
(green line) from normal colorectal tissue samples. AUC, area
under the curve; ROC, receiver operating characteristics; SPG20,
spastic paraplegia-20.
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OncogenesiRNA-mediated depletion of Spartin results in late
cytokinesis arrest and convoluted cytokinesis bridges
in HeLa and hTERT RPE-1 cells
To directly address a possible role of Spartin in
cytokinesis, we performed RNA interference experi-
ments using HeLa and hTERT RPE-1 cells. Western
blotting and immunoﬂuorescence analysis indicated an
efﬁcient and stable knockdown of Spartin (Supplemen-
tary Figures S8, S9A, and S10A). We next performed
quantitation of different mitotic stages in control and
Spartin-knockdown cells. Whereas there was no differ-
ence between control and short interfering RNA
(siRNA)-treated cells in the early stages of mitosis,
there was a signiﬁcant increase in the number of cells
in late cytokinesis upon Spartin depletion (oligo1:
P¼0.0029; oligo2: P¼0.001; independent-samples
t-test; Supplementary Figures S9B and S10B). More-
over, Spartin-depleted HeLa and hTERT RPE-1 cells
showed a signiﬁcantly slower growth rate compared
with control cells (Supplementary Figure S9C), indica-
ting a correlation between growth rate and cytokinesis
arrest similar to HT29 and SW480. Intriguingly,
we could observe convoluted cytokinesis bridges in
the Spartin-depleted cells (Supplementary Figures
S9D and E, and S10C–E), identical to the morphology
of HT29 and SW480. Aurora-B localized along the
Figure 2 Promoter methylation of SPG20 is associated with loss of gene expression. (a) Gene expression and DNA promoter
methylation status of SPG20 in cell lines. The quantitative gene expression levels are shown as ratios between the median of SPG20 and
the average of two endogenous controls, GUSB and ACTB.( b) Relative gene expression of SPG20 in colon cancer cell lines treated
with 1mM AZA for 72h, 0.5mM TSA for 12h and a combination of both drugs (AZAþTSA). AZA, 5-aza-20deoxycytidine; SPG20,
spastic paraplegia-20; TSA, trichostatin-A.
Figure 3 The SPG20-encoded protein Spartin is not expressed in hypermethylated colon cancer cell lines. (a) Western blot analysis
showing levels of Spartin expression in colon epithelial cell lines. (b–g) Immunoﬂuorescence confocal images of endogenous Spartin
(red) in the indicated cell lines. The pictures in panels b and d–g are generated using identical microscopy settings for comparison of the
Spartin level. The arrow points to a cytokinesis bridge (enlarged in panel c). The inset in panel c shows an overlay with phase-contrast
image to visualize the midbody. Nuclei are shown in blue. The cells are ﬁxed with 3% PFA. Size bars: 20mm. PFA, paraformaldehyde;
SPG20, spastic paraplegia-20.
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Oncogenewhole bridge, suggesting an arrest in very late cyto-
kinesis. These results indicate that Spartin is required
to complete cytokinesis in HeLa and hTERT RPE-1
cells, and the cytokinesis phenotype we observe in HT29
and SW480 is probably due to lack of Spartin in
these cells.
An arrest in cytokinesis is often accompanied by an
accumulation of binuclear cells (Fujiwara et al., 2005;
Figure 4 Spartin localizes to the spindle poles and the cytokinesis bridge of dividing cells. Three-dimensional reconstructions of
immunoﬂuorescence confocal images showing the localization of endogenous Spartin (red) to the cytokinesis bridge of HeLa cells (a–f)
and to the spindle poles of prometaphase in HeLa (g, h, k) and CRL-1790 (i, j) cells. a-Tubulin (a–c, g–i)o rg-tubulin (j, k) is shown in
green. Nuclei are shown in blue. Yellow indicates colocalization. The cells were pre-permeabilized with 0.05% saponin prior to ﬁxation
with 3% PFA (a–i) or ﬁxed directly in methanol (j, k). Size bars: 5mm. PFA, paraformaldehyde.
Figure 5 Colon cancer cell lines show several cytokinesis proﬁles. (a) The relative numbers of cells were quantiﬁed from
immunoﬂuorescence pictures using the Olympus Scan R microscope. (b) The cells were stained for a-tubulin and Aurora-B to visualize
cytokinesis proﬁles. The immunoﬂuorescence pictures were used to quantify the percentage of cells in cytokinesis. The error bars show
the ±s.e.m. of four independent experiments. In total, more than 3000 cells were counted for the CRL-1790 control line,
approximately 10000 for HT29, and SW480 and between 30000 and 40000 for the HCT116 and RKO lines. (c–f) Three-dimensional
reconstructions of immunoﬂuorescence confocal z-stack images showing the difference in the amount of cytokinesis proﬁles between
the four colon cancer cell lines (c, RKO; d, HCT116; e, SW480; f, HT29). Aurora-B (red), a-tubulin (green) and nuclei (blue).
The arrow points to a cytokinesis proﬁle. The cells were ﬁxed with 3% PFA. PFA, paraformaldehyde.
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OncogeneGanem et al., 2007; Steigemann et al., 2009). Surpris-
ingly, however, we were not able to detect any increase
in the number of binuclear cells in the Spartin-depleted
HeLa (Supplementary Figure S10B) and hTERT RPE-1
cells (data not shown). This might suggest that the cells
become arrested at a very late stage of cytokinesis, at a
point when regression of the cytokinesis furrow is no
longer possible.
Rescue of Spartin expression results in a normalization of
the cytokinesis process in HT29 colon cancer cells
To examine whether upregulation of Spartin expression
in cancer cells could reverse the cytokinesis phenotype
associated with SPG20 hypermethylation, we treated
initially non-expressing HT29 colon cancer cells as well
as CRL-1790 control cells with AZA. Both western
blotting and immunoﬂuorescence analysis conﬁrmed the
re-expression of moderate levels of Spartin in the HT29
cells after the treatment (Figure 7). AZA treatment had
no inﬂuence on the number of cytokinesis proﬁles in
CRL-1790 cells (P¼0.344) or hTERT RPE-1 cells (not
shown). However, the number of HT29 cells in
cytokinesis was signiﬁcantly reduced after AZA treat-
ment (P¼0.0008), indicating that re-expression of
Spartin results in a normalization of cytokinesis and
thereby prevents cytokinesis arrest. This was also
underscored by the normal morphology of the midbody
structures in the AZA-treated HT29 colon cancer cells.
By contrast, non-Spartin-expressing HT29 cells showed
several kinked, nicked or convoluted midbodies
(Figure 6), indicating problems with the ﬁnal abscission
step. The AZA treatment did not affect the proliferation
rate of either the HT29 colon cancer cells or the CRL-
1790 cells. These results are consistent with the idea that
the cytokinesis arrest observed in HT29 colon cancer
cells is due to SPG20 hypermethylation and consequent
downregulation of Spartin.
Discussion
In the present study we have used a quantitative high-
throughput methylation analysis to show that the
promoter of the SPG20 gene is hypermethylated in the
vast majority of colorectal carcinomas and adenomas.
The methylation was highly tumor-speciﬁc, underscored
by lack of SPG20 methylation in normal colorectal
mucosa samples. The ﬁndings have been validated in
clinically independent sample series, altogether counting
505 tissue samples. Using ROC SPG20 methylation
reached a very high area under the curve (AUC) value
for carcinomas and for adenomas versus normal
mucosa.
SPG20 methylation was also detected in a pilot series
of stool samples from patients with colorectal carcino-
ma, underscoring its potential as a biomarker for early
detection of colorectal cancer. Our ﬁnding that SPG20
promoter hypermethylation shuts down the expression
of Spartin, resulting in cytokinesis arrest, suggests a
Figure 6 ‘Slower’ growing colon cancer cell lines have convoluted cytokinesis bridges. A three-dimensional reconstruction of
immunoﬂuorescence confocal z-stack images showing the morphology of cytokinesis proﬁles in SW480 cells (a–c) and HT29 cells (d–e).
Aurora B (red), a-tubulin (green) and nuclei (blue). In addition to having convoluted cytokinesis bridges, both cell lines show
distribution of Aurora-B along the bridge, indicative of late cytokinesis proﬁles. The cells were pre-permeabilized with 0.05% saponin
prior to PFA ﬁxation (a, b) or ﬁxed directly with 3% PFA. Size bars, 5mm. PFA, paraformaldehyde.
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instability.
In contrast to genetic tests, which in most cases will
require several parallel analyses in order to establish the
mutation status of a single target gene (such as TP53),
DNA promoter methylation occurs at a deﬁned region
of the gene and is easily analyzed in a single cost-
effective reaction, thereby demanding less biological
starting material. Indeed, results from several studies of
stool and serum DNA underscore the potential of using
a non-invasive DNA methylation tests for early detec-
tion and/or screening for colorectal cancer (reviewed by
Zitt et al. (2007) and Kim et al. (2010)). However, in
spite of a few promising results (Mu ¨ ller et al., 2004;
Chen et al., 2005; Zhang et al., 2007; Devos et al., 2009),
speciﬁc and sensitive biomarkers to be included in an
effective non-invasive test are still lacking. SPG20
promoter hypermethylation has previously been shown
in ovarian cancers and proposed as a methylated target
in prostate cancer based on genome-wide analyses
(Goh et al., 2007; Kron et al., 2009). To the best of
our knowledge, this is the ﬁrst report identifying and
validating the methylation status of SPG20 in a large
cancer patient series, here shown for colorectal cancer.
The resulting high sensitivity and speciﬁcity identiﬁes
SPG20 as one of the most promising single biomarkers
for early detection of colorectal cancer.
By using real-time quantitative gene expression
analyses we showed that promoter hypermethylation
of SPG20 was associated with loss of gene expression.
This was conﬁrmed when the gene expression of SPG20
was restored in originally hypermethylated and non-
expressing colon cancer cell lines by removal of DNA
methylation using AZA. As expected, no Spartin protein
expression could be seen in the hypermethylated colon
cancer cell lines either by western blot analyses or by
immunoﬂuorescence confocal microscopy. Spartin ex-
pression was, however, seen in dividing control cells and
in the unmethylated HeLa and hTERT RPE-1 cell lines
where it, in accordance with previous ﬁndings, was
Figure 7 Rescue of Spartin expression results in the normalization of the cytokinesis process. Identical number of CRL-1790 cells
(a–d) and HT29 cells (f–i) were seeded out on coverslips and treated or not with 1mM AZA for 3 days as indicated in the ﬁgure. The
cells were ﬁxed with 3% PFA and stained for DNA (blue) and endogenous Spartin (red). (c, d, h, i) Magniﬁed views of the areas
indicated by white squares. (e, j) Western blots showing endogenous Spartin in AZA-treated versus that in non-treated cells. HT29
cells were treated (l) or not (k) with AZA, ﬁxed with 3% PFA and stained for Aurora-B (red), a-tubulin (green) and DNA (blue).
The difference in the number of cytokinesis proﬁles between AZA-treated and non-treated cells (arrowheads k, l) is shown in panel m.
(n) Quantitations of relative growth rates. The error bars show the ±s.d. of four independent coverslips. For each condition,
approximately 3000 cells were quantiﬁed for CRL-1790 and 30000 cells for HT29. AZA, 5-aza-20deoxycytidine; PFA,
paraformaldehyde.
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Oncogenelocated to the centrosome and midbody structures
(Robay et al., 2006).
Cytokinesis is the ﬁnal part of the M-phase of the cell
cycle, where the cytoplasm is divided between two
daughter cells. It is initiated by the assembly of a
contractile ring, which constricts the cell membrane into
generating a cleavage furrow. This ingresses until a
structure of densely packed microtubules, the midbody,
is formed. Subsequent cleavage of the midbody com-
pletes the cytokinesis (reviewed by Sagona and Stenmark
(2010)). Microtubule severing during the abscission
stage of cytokinesis is mediated by the AAA ATPase
Spastin, which is found at the midbody during cyto-
kinesis (Errico et al., 2004; Connell et al., 2009).
Interestingly, Spastin contains an MIT domain that is
closely related to that of Spartin (Ciccarelli et al., 2003).
Spastin is encoded by the SPG4 gene, which is mutated
in the most frequent form of autosomal dominant
spastic paraplegia (Hazan et al., 1999). Thus, Spastin
not only has structural similarity to Spartin, but also
shares its association with spastic paraplegia. This opens
the possibility that these two proteins could function in
the same pathway.
Based on the midbody localization of Spartin as well
as its common features with Spastin, we hypothesized
that Spartin as well could have a role in cytokinesis.
To provide insight into the underlying biology of SPG20
hypermethylation in cancer cells, we investigated cell
proliferation in Spartin-deﬁcient colon cancer cell lines
and discovered that the ‘slower’ proliferating cell
lines showed signiﬁcantly more cytokinesis proﬁles and
convoluted midbody structures compared with the
highly proliferative cell lines. HeLa and hTERT RPE-
1 cells in which Spartin expression was knocked down
by siRNA conﬁrmed the phenotype seen among the
‘slower’ growing colon cancer cell lines by showing
cytokinesis arrest as well as convoluted midbodies.
Interestingly, a strikingly similar midbody morphology
has been reported in cells with knockdown of Spastin
(Connell et al., 2009). When the Spartin protein was re-
expressed in initially non-expressing HT29 colon cancer
cells, the number of cells arrested in late cytokinesis was
signiﬁcantly reduced. Taken together, these observa-
tions show that the multifunctional Spartin protein also
has a role in cytokinesis. This novel role of the Spartin
protein was recently also reported by Renvoise et al.
(2010), who showed that Spartin colocalized with Ist1
(an endosomal sorting complex required for transport;
ESCRT protein) at the midbody of HeLa cells and that
depletion of Spartin with siRNA markedly impaired
cytokinesis.
Failure of cytokinesis and subsequent aneuploidy has
been shown to be associated with carcinogenesis
(reviewed by Sagona and Stenmark, 2010). In cells
experiencing cytokinesis arrest, a regression of the
cytokinesis furrow can result in binuclearity (Fujiwara
et al., 2005; Ganem et al., 2007; Steigemann et al., 2009).
Although a signiﬁcant increase in the number of
multinucleated Spartin-depleted HeLa cells was re-
ported by Renvoise et al. (2010), binuclear Spartin-
deﬁcient cells were not observed in the present study
either in HeLa cells or colon cancer cells. It is also worth
noting that Spastin-deﬁcient cells, similarly to Spartin-
deﬁcient cells, show cytokinesis arrest without a bi-
nuclear phenotype (Connell et al., 2009), which further
emphasizes the possible functional relationship between
these two proteins. The lack of binuclear cells might
suggest that the cells become arrested at a very late stage
of cytokinesis where abortion of cytokinesis is no longer
possible. The functional consequences of the cytokinesis
arrest induced by Spartin downregulation therefore
remain somewhat enigmatic. Cytokinesis failure in the
absence of midbody regression has three alternative
outcomes—an eventual (albeit delayed) midbody abscis-
sion, activation of apoptotic cell death (Bu et al., 2008;
Connell et al., 2009) or proliferation of cells that remain
interconnected by thin intercellular bridges. Delayed
abscission is associated with chromosomal instability
(Fujiwara et al., 2005; Ganem et al., 2007), whereas
interconnected cells tend to show synchronized
responses to proliferation and differentiation cues
(Ventela ¨ et al., 2003; Vidulescu et al., 2004; Pointis
et al., 2010). Both these mechanisms might thus
contribute to carcinogenesis. Interestingly, both the
‘slower’ proliferating colon cancer cell lines included in
the present study (HT29 and SW480) have a chromo-
somal unstable phenotype (Lengauer et al., 1997).
In the present study, we observed that, even though
colon cancer cell lines with convoluted midbodies have
a lower proliferation rate than cancer lines without
cells arrested in late cytokinesis, they still proliferate
signiﬁcantly faster than control cells. This might be
explained by the presence of multiple additional aber-
rations accumulated during tumorigenesis, which pro-
vides the cancer cells with a selective advantage. The
nature of such additional aberrations might also explain
why we observed a delay in cytokinesis and the presence
of several cytokinesis bridges only in half of the colon
cancer cell lines tested, although all of them lacked
expression of Spartin. The MSS and MSI developmental
pathways are characterized by accumulation of distinct
aberrations. The latter group, which accounts for
approximately 15% of sporadic colorectal cancers, has
a defect in the DNA mismatch repair system leading to
frequent aberrations in microsatellites, but the tumors
are typically near diploid. On the other hand, the
majority of sporadic colorectal carcinomas (B85%) are
microsatellite stable (MSS), but typically contain multi-
ple chromosomal aberrations (that is, aneuploid). The
molecular basis of the MSS phenotype in Spartin-
deﬁcient colon cancer cells is not clariﬁed, but a possible
mechanism is that aberrant cytokinesis may lead to
chromosome-containing intercellular bridges that even-
tually lead to reduced ﬁdelity in chromosome distribu-
tion (Steigemann et al., 2009).
A number of additional roles have been described for
the Spartin protein, including in endocytosis and
degradation of epidermal growth factor receptor (Ba-
kowska et al., 2007), and regulation of the size and
number of lipid droplets (Eastman et al., 2009; Hooper
et al., 2010). Cells lacking expression of Spartin will
therefore suffer aberrations in several cellular mechan-
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them more prone to accumulate additional aberrations.
In the present study, we showed that hypermethylation
of SPG20 and subsequent loss of gene and protein
expression is an early and frequent event in colorectal
tumorigenesis. SPG20 hypermethylation was present in
the majority of early precursor lesions, adenomas. Only
a small fraction of these benign tumors, (the ones that
accumulate aberrations necessary for malignant trans-
formation) will progress into malignant carcinomas.
In summary, detection and quantiﬁcation of SPG20
promoter methylation is a highly speciﬁc and sensitive
biomarker for colorectal tumors. Analyses of a pilot of
stool samples from colon cancer patients indicate that
SPG20 promoter methylation can be detected in such
samples, which is very promising for further development
of SPG20 as a biomarker in non-invasive tests. This
should be explored further using stool or plasma samples
from large test groups. We further show that promoter
hypermethylation of SPG20 is associated with loss of gene
expression and subsequent lack of Spartin protein. The
presence of aberrant cytokinesis proﬁles as well as
convoluted midbodies in Spartin-depleted HeLa and
hTERT RPE-1 cells, and Spartin-deﬁcient ‘slower’ grow-
ing colon cancer cell lines reveals a function for the
Spartin protein also in cytokinesis. Our data not only
identify a promising biomarker for colorectal cancer, but
also reveal a cellular mechanism that could be involved in
the early carcinogenic process.
Materials and methods
Cancer cell lines, patients and tissue samples
The present study includes 20 colon cancer cell lines,
CRL-1790 and hTERT RPE-1 (epithelial lines from normal
colon and retina, respectively), and 30 cell lines representative
of breast, cervix, gastric, kidney, ovary, pancreas, prostate and
uterus cancer (see Supplementary information for details).
Six of the colon cancer cell lines (MSI: HCT15, RKO and
SW48; MSS: HT29, LS1034 and SW480) were subjected to
epigenetic treatment using the demethylating drug AZA (1mM
for 72h; Sigma-Aldrich, St Louis, MO, USA), the histone
deacetylase inhibitor TSA (0.5mM for 12h; Sigma-Aldrich) and
a combination of both drugs (1mM AZA for 72h and 0.5mM
TSA added the last 12h). In parallel, the same cell lines were
cultured without treatment for 72h.
Four hundred tissue samples divided between test and
validation sets were analyzed, including 179 colorectal
carcinomas (47 MSI; 26% and 132 MSS; 74%), 111 adenomas
and 110 normal mucosa samples. The test and validation sets
were from clinically independent sample series (Supplementary
Table S1). Additionally, normal mucosa samples (n¼105) taken
in distance from the carcinomas included in the validation set
were analyzed.
Paired colorectal carcinoma and stool samples from nine
patients were analyzed, including a stool sample taken proximally
from the colorectal carcinoma (during surgery; see Supplementary
information).
Qualitative and quantitative MSP
Bisulﬁte-treated DNA from cancer cell lines was analyzed by
qualitative methylation-speciﬁc PCR (MSP), whereas clinical
samples were analyzed by qMSP (see Supplementary Table S2
for the primer sequences and Supplementary information for
assay details).
Bisulﬁte sequencing
Bisulﬁte sequencing primers were designed using Methyl Primer
Express v1.0 (Applied Biosystems, Carlsbad, CA, USA) and
purchased from MedProbe. Two fragments were designed in
order to fully cover the area ampliﬁed by MSP and qMSP
(Supplementary Figure S1). See Supplementary Table S2 for
primer sequences. A representative promoter region of SPG20 was
subjected to direct bisulﬁte sequencing in 20 colon cancer cell lines.
Real-time quantitative gene expression analysis
Forty-nine cell lines, 111 colorectal carcinomas (100 methy-
lated and 11 unmethylated) and 41 normal mucosa samples
(all unmethylated) were subjected to quantitative mRNA
analysis. Prior to the analysis, the high-capacity cDNA archive
kit (Applied Biosystems) was used to convert total RNA to
cDNA. cDNA was ampliﬁed in separate 384-wells plates using
the Hs00374834_m1 assay for SPG20, and Hs99999903_m1
and Hs99999908_m1 for the endogenous controls, ACTB and
GUSB, respectively. Samples were analyzed in triplicates
according to the manufacturer’s protocol using the 7900HT
Sequence Detection System (Applied Biosystems). A standard
curve was generated from a serial dilution of cDNA generated
from the human universal reference RNA (Agilent Techno-
logies, Santa Clara, CA, USA). To adjust for potential
variation in the template amount in the individual reactions,
the median gene expression value from the SPG20 assay was
normalized against the mean value of the endogenous controls.
Antibodies and ﬂuorescent probes
Rabbit anti-Spartin was purchased from Protein Tech Group
Inc. (Chicago, IL, USA). Rabbit anti-Aurora-B was from
Abcam (Cambridge, UK). Mouse anti-a-tubulin, g-tubulin
and Hoechst 33342 were from Sigma-Aldrich.
siRNA transfection
The non-targeting RNA duplex and the Spartin siRNA duplexes
were from Invitrogen (Carlsbad, CA, USA) and have been
published before (see references Cabezas et al. (2005) and
Bakowska et al. (2007), respectively). HeLa and hTERT RPE-1
cells grown in six-well plates were transfected with Lipofectamin
RNAiMax (Invitrogen) and 50nM siRNA the same day as they
were seeded. The next day they were split and seeded out onto
coverslips where they could grow for 2, 3 or 4 days. Separate
transfections were performed for the different time points.
Confocal ﬂuorescence microscopy
The cells were permeabilized or not with 0.05% saponin, ﬁxed
with 3% paraformaldehyde (PFA) or methanol, and stained for
ﬂuorescence microscopy as described by Simonsen et al. (1998).
Coverslips were analyzed with a Zeiss LSM 710 laser scanning
system equipped with an invert Axio Observer.Z1 microscope
using a Plan-Apochromat X63/1.4 Oil DICII objective. Pictures
were analyzed using the ZEN 2009 Light Edition software.
High-content analysis of growth rate and cytokinesis proﬁles
Cells ﬁxed in 3% PFA were stained for a-tubulin, Aurora-B
and DNA. Images were taken with an Olympus Scan R
microscope and analyzed as previously described by Sagona
et al. (2010). For relative cell growth analysis, the number of
cells obtained from the CRL-1790 normal colon epithelial cell
line was set to 1 for each experiment.
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OncogeneEthics
All samples belong to approved research biobanks registered
at the Norwegian Institute of Public Health. The present
research project has been approved by the Regional Ethics
Committee and National Data Inspectorate of Norway.
Statistical analysis
SPSS v16.0 was used for statistical analyses. Pearson’s w
2
and Fisher’s exact tests were used for categorical variables.
The relationship between promoter methylation status and
gene expression was analyzed using t-test (cell lines) and
Mann–Whitney (tissue) test. ROC curves were generated using
percentage methylated reference values. All P-values derived
from two-tailed tests.
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